Open Orphan, Russ Mould and Paul Hill
Justin Waite
Vox Markets Podcast with Justin Waite
12:58, 22nd May 2020

Vox Media Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: Open Orphan, Russ Mould and Paul Hill

Cathal Friel, Executive Chairman of Open Orphan (ORPH) FOLLOW describes what the proceeds of their £12m fund raising will be used for.

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the provision of viral laboratory services and the testing of vaccine and antivirus using human challenge study models. Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences, and Open Orphan Genomic Health Data.


Russ Mould, Investment Director at stockbroker AJ Bell discusses the slew of companies conducting equity fundraises and if its possible to accurately value a company at the moment.

(Interview starts at 10 minutes 43 seconds)


Paul Hill, full time investor and equity analyst gives his view on the market and mentions:

Lloyds (LLOY) FOLLOW

Elecosoft (ELCO) FOLLOW

Northbridge (NBI) FOLLOW

Aviva (AV.) FOLLOW

ClearStar (CLSU) FOLLOW

Accesso Technology (ACSO) FOLLOW

(Interview starts at 26 minutes 13 seconds)  

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist